SynthesisFamilial cancer2018
Association between miR-146a rs2910164 polymorphism and specific cancer susceptibility: an updated meta-analysis.
Synthesis in Familial cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The MMPBiomolecules · 2019Pooled it
- Association of rs2910164 polymorphism in MiR-146a gene with psoriasis susceptibility: A meta-analysis.Medicine · 2019Pooled it
- Genetic Polymorphisms of miR-146a and miR-155 in Psoriasis and Psoriatic Arthritis: Evidence from a Turkish Case-Control Study.Dermatology practical & conceptual · 2026Article
- miR-146b-5p promotes prostate cancer progression by targeting and negatively regulating FOXO3 and its mechanism.World journal of surgical oncology · 2026Article
- Review
- Association between miR-146a rs2910164, miR-196a2 rs11614913, and miR-499 rs3746444 polymorphisms and the risk of esophageal carcinoma: A case-control study.Cancer medicine · 2022Article
- Exosomal miRNA-146a is downregulated in clear cell renal cell carcinoma patients with severe immune-related adverse events.Non-coding RNA research · 2022Article
- Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis.Biomedicines · 2022Review
- Non-Coding RNA Polymorphisms (rs2910164 and rs1333049) Associated With Prognosis of Lung Cancer Under Platinum-Based Chemotherapy.Frontiers in pharmacology · 2021Article
- The rate of miR-146a rs2910164 mutations in patients with lung cancer: a meta-analytic review.Translational cancer research · 2020Article
- Expression of miRNA in 5-FU resistant esophageal cancer.Molecular and clinical oncology · 2020Article
- MiRNA-146a Polymorphism Was Not Associated with Malaria in Southern India.The American journal of tropical medicine and hygiene · 2020Article
- The miR-146a SNP Rs2910164 and miR-155 SNP rs767649 Are Risk Factors for Non-Small Cell Lung Cancer in the Iranian Population.Canadian respiratory journal · 2020Article
- Genetic polymorphisms and gastric cancer risk: a comprehensive review synopsis from meta-analysis and genome-wide association studies.Cancer biology & medicine · 2019Article
- A genetic variant in miR-100 is a protective factor of childhood acute lymphoblastic leukemia.Cancer medicine · 2019Article
- MiRNA-146a polymorphism increases the odds of malaria in pregnancy.Malaria journal · 2019Article
- Candidate Genes and MiRNAs Linked to the Inverse Relationship Between Cancer and Alzheimer's Disease: Insights From Data Mining and Enrichment Analysis.Frontiers in genetics · 2019Article
- Relationship between CT signs and the expression of miR-146a in colon cancer.Oncology letters · 2018Article
- miR-1269 promotes cell survival and proliferation by targeting tp53 and caspase-9 in lung cancer.OncoTargets and therapy · 2018Article
- miR-300 rs12894467 polymorphism may be associated with susceptibility to primary lung cancer in the Chinese Han population.Cancer management and research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapidly increasing of cancer risk nationwide and worldwide has threatened human health and caused the changes of disease and death spectrum. MicroRNA (MiRNA) as cancer biomarker on susceptibility has enjoyed a high level of concern. This article will discuss the association between miR-146 rs2910164 polymorphism and cancer susceptibility in 38 independent case-control studies from 34905 individuals. The 38 case-control studies which were searched from PubMed were used for conducting a meta-analysis. There were 14670 cases and 20235 controls. ORs and 95% CIs were used for reflecting the strength of association between miR-146a rs2910164 polymorphism and cancer susceptibility. Subgroup analysis based on the cancer type, ethnicity and study designs. All analysis were performed by using the Stata 11.0 software. MiR-146a rs2910164 polymorphism and overall cancer susceptibility were significantly uncorrelated in all genetic models. In the subgroup analysis for cancer types, miR-146a rs2910164 polymorphism was associated with the susceptibility of lung cancer (CC vs. GG: OR 1.275, 95% CI 1.117-1.455 (P = 0.000); CC + CG vs. GG: OR 1.166, 95% CI 1.052-1.293 (P = 0.003); CC vs. CG + GG: OR 1.239, 95% CI 1.116-1.375 (P = 0.000); C vs. G OR 1.151, 95% CI 1.080-1.227 (P = 0.000)) and nasopharyngeal carcinoma (CC vs. GG: OR 1.713, 95% CI 1.183-2.479 (P = 0.004); CC vs. CG + GG: OR 1.672, 95% CI 1.330-2.103 (P = 0.000); C vs. G: OR 1.400, 95% CI 1.181-1.659 (P = 0.000)), but it was not associated with hepatocellular carcinoma and gastric cancer. However, in the other subgroup analysis by ethnicity and study designs, no significant associations were found. MiR-146a rs2910164 polymorphism might be associated with the susceptibility to lung cancer and nasopharyngeal carcinoma.
Indexed as
Identifiers
29127520What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.